Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tito Fojo

Showing results (61-70 of 237) with videos related to

Pageof 24
Sort By:
JAMA Oncology|August 24, 2023
In Defense of Neuroendocrine Tumor Trials-ReplyBrian W Labadie, Antonio Tito Fojo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2009
Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinomaIrina Veytsman, Lynnette Nieman, Tito Fojo
The Oncologist|March 27, 2014
Clinical trial results: a clinical trial bazaar!Antonio Tito Fojo, Susan E Bates
The Oncologist|September 8, 2023
Adjuvant Capecitabine for Biliary Cancer and the Importance of Looking Beyond P-ValuesAntonio Tito Fojo, Alfred I Neugut
The Oncologist|March 18, 2024
The Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as ArchetypeTito Fojo, Meredith LaRose, Susan E Bates
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2014
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patientsVinay Prasad, Paul R Massey, Tito Fojo
The Oncologist|January 31, 2012
Editor's Note ...Clinical Trial Reports: A New SectionTito Fojo, Susan Bates, Bruce A Chabner
Nature Reviews. Clinical Oncology|February 1, 2012
Hazard ratios in cancer clinical trials--a primerKrastan B Blagoev, Julia Wilkerson, Tito Fojo
The Oncologist|October 8, 2003
The role of ABC transporters in clinical practiceGregory D Leonard, Tito Fojo, Susan E Bates
Gynecologic Oncology|June 25, 2003
Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analogManish Agrawal, Maureen Edgerly, Tito Fojo, et al.
Pageof 24

Showing results (61-70 of 237) with videos related to

Sort By:
Pageof 24
JAMA Oncology|August 24, 2023
In Defense of Neuroendocrine Tumor Trials-ReplyBrian W Labadie, Antonio Tito Fojo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2009
Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinomaIrina Veytsman, Lynnette Nieman, Tito Fojo
The Oncologist|March 27, 2014
Clinical trial results: a clinical trial bazaar!Antonio Tito Fojo, Susan E Bates
The Oncologist|September 8, 2023
Adjuvant Capecitabine for Biliary Cancer and the Importance of Looking Beyond P-ValuesAntonio Tito Fojo, Alfred I Neugut
The Oncologist|March 18, 2024
The Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as ArchetypeTito Fojo, Meredith LaRose, Susan E Bates
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2014
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patientsVinay Prasad, Paul R Massey, Tito Fojo
The Oncologist|January 31, 2012
Editor's Note ...Clinical Trial Reports: A New SectionTito Fojo, Susan Bates, Bruce A Chabner
Nature Reviews. Clinical Oncology|February 1, 2012
Hazard ratios in cancer clinical trials--a primerKrastan B Blagoev, Julia Wilkerson, Tito Fojo
The Oncologist|October 8, 2003
The role of ABC transporters in clinical practiceGregory D Leonard, Tito Fojo, Susan E Bates
Gynecologic Oncology|June 25, 2003
Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analogManish Agrawal, Maureen Edgerly, Tito Fojo, et al.
Pageof 24